According to a new report, published by KBV research, The Global Dry Eye Treatment Devices Market size is expected to reach $348.8 million by 2028, rising at a market growth of 7.4% CAGR during the forecast period.
The Meibomian Gland Expression (MGX) market is leading the segment in the Global Dry Eye Treatment Devices Market by Technology in 2021; thereby, achieving a market value of $149.4 million by 2028. It is because the most common cause of dry eye disease, Meibomian Gland Dysfunction (MGD), is treated effectively with MGX. Utilizing tools like forceps, warm compressors, and thermal pulsation systems, assists in addressing the obstruction that is present around the periorbital gland and aids in removing it.
The Hospitals market is experiencing a CAGR of 7.5% during (2022 - 2028). This is due to the fact that hospitals are being given a high preference because the bulk of pharmaceuticals may only be administered following careful evaluations by qualified medical specialists.
The North America market dominated the Global Dry Eye Treatment Devices Market by Region in 2021; thereby, achieving a market value of $129.1 million by 2028. The Europe market is exhibiting a CAGR of 6.9% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 8.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/dry-eye-treatment-devices-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of MiBo Medical Group, Sight Sciences, Inc., Lumenis Ltd., ESW Vision SAS, Johnson & Johnson Vision Care, Inc. and Alcon, Inc.
By Technology
By End User
By Geography
Companies Profiled
Unique Offerings 
